AU2016307889A1 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors - Google Patents
Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors Download PDFInfo
- Publication number
- AU2016307889A1 AU2016307889A1 AU2016307889A AU2016307889A AU2016307889A1 AU 2016307889 A1 AU2016307889 A1 AU 2016307889A1 AU 2016307889 A AU2016307889 A AU 2016307889A AU 2016307889 A AU2016307889 A AU 2016307889A AU 2016307889 A1 AU2016307889 A1 AU 2016307889A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound according
- mmol
- fluoro
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DZRIXLUFXJVNSI-UHFFFAOYSA-N O=Cc(cn1)cc2c1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1 Chemical compound O=Cc(cn1)cc2c1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1 DZRIXLUFXJVNSI-UHFFFAOYSA-N 0.000 description 5
- 0 CN(*)Cc(cn1)cc2c1[o]c1c2nc(-c2c(cc[n]3)c3ccc2)nc1N1CCOCC1 Chemical compound CN(*)Cc(cn1)cc2c1[o]c1c2nc(-c2c(cc[n]3)c3ccc2)nc1N1CCOCC1 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N O=S1(CCNCC1)=O Chemical compound O=S1(CCNCC1)=O NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- RKIRNQUUFNADPX-UHFFFAOYSA-N O=S1CCN(Cc(cc2c3n4)cnc2[o]c3c(N2CCOCC2)nc4Cl)CC1 Chemical compound O=S1CCN(Cc(cc2c3n4)cnc2[o]c3c(N2CCOCC2)nc4Cl)CC1 RKIRNQUUFNADPX-UHFFFAOYSA-N 0.000 description 2
- CAWRLEYAOIYGPN-ROUUACIJSA-N C(c(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1)N1[C@@H](C2)CS[C@@H]2C1 Chemical compound C(c(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1)N1[C@@H](C2)CS[C@@H]2C1 CAWRLEYAOIYGPN-ROUUACIJSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N C1NCCSC1 Chemical compound C1NCCSC1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- LTQBUWVDIKUNHJ-WHFBIAKZSA-N C1[C@@H]2SC[C@H]1NC2 Chemical compound C1[C@@H]2SC[C@H]1NC2 LTQBUWVDIKUNHJ-WHFBIAKZSA-N 0.000 description 1
- STRAMSCPUJKXDU-UHFFFAOYSA-N CC(NC1N2CCOCC2)=Nc2c1[o]c1ncc(C=O)cc21 Chemical compound CC(NC1N2CCOCC2)=Nc2c1[o]c1ncc(C=O)cc21 STRAMSCPUJKXDU-UHFFFAOYSA-N 0.000 description 1
- TYSSDDNGMHOPRP-UHFFFAOYSA-N CC(c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N(CC1)CCS1(=O)=O Chemical compound CC(c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N(CC1)CCS1(=O)=O TYSSDDNGMHOPRP-UHFFFAOYSA-N 0.000 description 1
- JUAGBRCZHMHUFN-UHFFFAOYSA-N CC1(C)OB(c2c(cc[nH]3)c3cc(Cl)c2)OC1(C)C Chemical compound CC1(C)OB(c2c(cc[nH]3)c3cc(Cl)c2)OC1(C)C JUAGBRCZHMHUFN-UHFFFAOYSA-N 0.000 description 1
- QDCIXBBEUHMLDN-UHFFFAOYSA-N CC1(C)OB(c2c(cc[nH]3)c3ccc2)OC1(C)C Chemical compound CC1(C)OB(c2c(cc[nH]3)c3ccc2)OC1(C)C QDCIXBBEUHMLDN-UHFFFAOYSA-N 0.000 description 1
- DOARAXALTUDURU-UHFFFAOYSA-N CNCc(cn1)cc2c1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1 Chemical compound CNCc(cn1)cc2c1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1 DOARAXALTUDURU-UHFFFAOYSA-N 0.000 description 1
- IVLSLXMGGISLJT-MRVPVSSYSA-N C[C@H](c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N Chemical compound C[C@H](c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N IVLSLXMGGISLJT-MRVPVSSYSA-N 0.000 description 1
- ASAAICTVGLYLRH-UHFFFAOYSA-N Cc(nc1N2CCOCC2)nc2c1[o]c1ncc(C=O)cc21 Chemical compound Cc(nc1N2CCOCC2)nc2c1[o]c1ncc(C=O)cc21 ASAAICTVGLYLRH-UHFFFAOYSA-N 0.000 description 1
- AYQRUVBPLGICNU-UHFFFAOYSA-N Cc1nc(N2CCOCC2)c2[o]c3ncc(CN(CC4)CCS4=O)cc3c2n1 Chemical compound Cc1nc(N2CCOCC2)c2[o]c3ncc(CN(CC4)CCS4=O)cc3c2n1 AYQRUVBPLGICNU-UHFFFAOYSA-N 0.000 description 1
- JSHJFDUDNNDHOX-STQMWFEESA-N Clc(nc1N2CCOCC2)nc2c1[o]c1ncc(CN3[C@@H](C4)CS[C@@H]4C3)cc21 Chemical compound Clc(nc1N2CCOCC2)nc2c1[o]c1ncc(CN3[C@@H](C4)CS[C@@H]4C3)cc21 JSHJFDUDNNDHOX-STQMWFEESA-N 0.000 description 1
- PMIGAISGWPTELT-UHFFFAOYSA-N N#Cc1c[nH]c2cccc(Br)c12 Chemical compound N#Cc1c[nH]c2cccc(Br)c12 PMIGAISGWPTELT-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N O=S1CCNCC1 Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- USJUQEVUEBCLLR-UHFFFAOYSA-N OB(c1cccc2c1cc[nH]2)O Chemical compound OB(c1cccc2c1cc[nH]2)O USJUQEVUEBCLLR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514754.9 | 2015-08-19 | ||
| GBGB1514754.9A GB201514754D0 (en) | 2015-08-19 | 2015-08-19 | Compounds |
| PCT/GB2016/052581 WO2017029521A1 (en) | 2015-08-19 | 2016-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016307889A1 true AU2016307889A1 (en) | 2018-03-08 |
Family
ID=54258853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016307889A Abandoned AU2016307889A1 (en) | 2015-08-19 | 2016-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10442815B2 (https=) |
| EP (1) | EP3337807A1 (https=) |
| JP (1) | JP2018528942A (https=) |
| CN (1) | CN108349988B (https=) |
| AU (1) | AU2016307889A1 (https=) |
| CA (1) | CA2995909A1 (https=) |
| GB (1) | GB201514754D0 (https=) |
| MX (1) | MX2018001992A (https=) |
| WO (1) | WO2017029521A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN01325A (https=) | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| US20230038929A1 (en) | 2019-12-05 | 2023-02-09 | Verge Analytics, Inc. | Fused Tricyclic Heterocyclic Compounds and Uses Thereof |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| JP2004502686A (ja) | 2000-06-30 | 2004-01-29 | スージェン・インコーポレーテッド | ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用 |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| WO2006127587A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| CN101511840A (zh) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| RU2008141356A (ru) | 2006-04-26 | 2010-06-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k) |
| ES2365258T3 (es) * | 2006-06-26 | 2011-09-27 | Ucb Pharma S.A. | Derivados de tiazol condensados como inhibidores de quinasa. |
| KR20090087027A (ko) | 2006-11-13 | 2009-08-14 | 일라이 릴리 앤드 캄파니 | 염증 질환 및 암의 치료를 위한 티에노피리미디논 |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| US20100063032A1 (en) | 2007-03-28 | 2010-03-11 | Debenham John S | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| CA2742550A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| IN2012DN01325A (https=) * | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN103702990B (zh) | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| RU2015118647A (ru) | 2012-11-20 | 2017-01-10 | Дженентек, Инк. | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr |
| NZ714283A (en) | 2013-05-10 | 2020-04-24 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| SG11201509842SA (en) | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014210354A1 (en) * | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
-
2015
- 2015-08-19 GB GBGB1514754.9A patent/GB201514754D0/en not_active Ceased
-
2016
- 2016-08-19 US US15/753,358 patent/US10442815B2/en active Active
- 2016-08-19 EP EP16756767.6A patent/EP3337807A1/en not_active Withdrawn
- 2016-08-19 JP JP2018508666A patent/JP2018528942A/ja not_active Withdrawn
- 2016-08-19 CN CN201680058333.7A patent/CN108349988B/zh active Active
- 2016-08-19 WO PCT/GB2016/052581 patent/WO2017029521A1/en not_active Ceased
- 2016-08-19 AU AU2016307889A patent/AU2016307889A1/en not_active Abandoned
- 2016-08-19 MX MX2018001992A patent/MX2018001992A/es unknown
- 2016-08-19 CA CA2995909A patent/CA2995909A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001992A (es) | 2018-06-19 |
| WO2017029521A1 (en) | 2017-02-23 |
| CN108349988A (zh) | 2018-07-31 |
| GB201514754D0 (en) | 2015-09-30 |
| CA2995909A1 (en) | 2017-02-23 |
| US10442815B2 (en) | 2019-10-15 |
| US20180244685A1 (en) | 2018-08-30 |
| EP3337807A1 (en) | 2018-06-27 |
| CN108349988B (zh) | 2021-10-01 |
| JP2018528942A (ja) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016307889A1 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| US11708378B2 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| EP2822943B1 (en) | Phosphoinositide 3-kinase inhibitors | |
| KR20250113487A (ko) | 화합물 | |
| US10377764B2 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| KR20180063895A (ko) | 단백질 키나제 억제제로서의 벤조락탐 화합물 | |
| EP4055021A1 (en) | Heterocyclic rip1 inhibitory compounds | |
| CN108348505A (zh) | 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 | |
| RU2797295C1 (ru) | Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью | |
| HK1227870A1 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| HK1227870B (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |